eMIMS New Product
Protelos safety update
20-Dec-07
The MHRA has issued advice stating that women taking the postmenopausal osteoporosis drug strontium ranelate (Protelos) should be alert to the risk of severe allergic reactions.
If patients develop a rash they should stop taking the drug and consult their doctor immediately. Once treatment has been stopped it should not be re-introduced.
The MHRA advice follows a European Medicines Agency (EMEA) recommendation that the product information for Protelos should be changed to include warnings on severe hypersensitivity syndromes as an urgent measure.
Up to 16 November 2007, the EMEA had received 16 reports of ‘drug rash with eosinophilia and systemic symptoms (DRESS)’ in patients treated with Protelos/Osseor (brand name in some other countries), two of which were fatal.
Further information: MHRA
Tools
Jobs
Job of the Week
- Salaried GP North West England
- Full Time Salaried GP
- GP Locum Regular / Long Term West Midlands
- Salaried GP Central London
- Full-Time Salaried GP Central London
- Full time Salaried GP West Midlands
- Partner North West England
- Registered Medical Practitioners
- GPs Australasia
- Locum GP West Midlands
Comments
Margaret Graham
24/01/2008
Not unexpected when using a treatment involving heavy metal
Only registered users may comment. Log in now or register for a free account.
There are problems with your form submission.
Please review the errors shown below.